Table 1 Details of the papers describing clinical trials with MSCs for the treatment of joint diseases
From: Chondromalacia patellae: current options and emerging cell therapies
References | Cell types/source | Applications | Delivery intervention | Study type | Patient No. | Results | |
|---|---|---|---|---|---|---|---|
Adverse | Beneficial | ||||||
[84] | hBM-MSC | kOA | Injection of 20–24×106 cells | Original article | 6 | One year, no local or systemic adverse events | Increase: functional, thickness, repair tissue over the subchondral bone Decrease: edematous and pain |
[70] | hADSCs | CMP | The ADSCs along with PRP, hyaluronic acid, and CaCl2 | Case report | 3 | 18 months, all three patients did not report any serious side effects | Increase: the damaged tissues (softened cartilages) Decrease: pain |
[85] | hUCB-MSCs | Osteochondral defect | Injection of MSC (5 × 106/ml) in HA (4%) | Case report | 1 | 5.5 years, no specific adverse reactions | Increase: IKDC, WOMAC, cartilage-like aspect, GAGs, Collagen type II Decrease: VAS and collagen type I, no bone formation |
[86] | hUCB-MSCs | OA | Injection of MSC (1.15/1.25 × 107 or 1.65/2 × 107) in HA | Open-label, single-arm, phase I/II | 7 | 7 years, no cases of osteogenesis or tumorigenesis; mild to moderate treatment-emergent adverse events | Increase: IKDC and aspect of hyaline-like cartilage Decrease: VAS |
[87] | hUC-MSCs | KOA | Injection of UC MSC (20×106) once or twice vs HA injection | Randomized double-blind, controlled phase I/II | 29 | No serious AEs, deaths, permanent disability, neoplasia, or septic arthritis cases; acute synovitis and mild to moderate symptomatic effusion | Increase: WOMAC, decrease: VAS, pain, and disability |
[80] | hBM-MSCs | KOA | Injection of BM MSCs (1 × 106/10 × 106/50 × 106) | Nonrandomized, open-label, dose-escalation phase I/II clinical trial conducted | 12 | 12 months, no serious adverse events; minor, transient adverse events | Improvement in KOOS pain, symptoms, quality of life, and WOMAC stiffness |
[88] | hUCB-MSCs | OA | Injection of hUCB-MSC (7.5 × 106) in HA(4%)-Commercial | Retrospective case series | 128 | 2 years, no adverse reactions or postoperative complications were noted | Increase: IKDC, ,WOMAC, and MOCART Decrease: VAS |
[89] | hUC-MSCs | KOA | Injection of wjMSC (10 × 106) in 2 ml secretome + 2 ml HA | Open-label, single-arm, phase I/II | 29 | 3.5 years, no adverse reactions are reported | Increase: IKDC and WOMAC Decrease: VAS |